Neuralink商标前持有者惊觉，原来年初的买家是钢铁侠！Neuralink商标前持有者惊觉，原来年初的买家是钢铁侠！机友之家百家号前不久， 粹客网 曾报道，Space X 和特斯拉的 CEO Elon Musk 在他脑洞大开的“疯狂清单”中再添一员—— 旨在开发可提升人类脑能力的脑机界面 公司 Neuralink。此消息传出后，美国俄亥俄州一名神经科学教授才惊觉，原来今年一月份把他们的商标“Neuralink”买走的人是 Elon Musk 啊！这位名为 Pedram Mohseni 的教授就职于凯斯西储大学。从 2011 年开始，他便和堪萨斯大学医学中心的脑科专家 Randolph Nudo 一起研究如何使用大脑芯片技术来治疗脑损伤疾病。在验证了这项技术可以在某种程度上重建小鼠脑受损部位的神经连接后，他们于 2015 年共同成立了初创公司——Neuralink，并拥有该商标的所有权。公司成立后，两人致力于完善大脑芯片技术，希望将这种治疗脑损伤的植入设备做到像瑞士钟表一样可靠，为未来推广这项技术创造条件。不过，他们光是开发和测试脑芯片就用掉了两亿美元，加上公司在融资上几乎没有取得任何进展。因此，当年初有陌生人上门，表示要以数万美元购买“Neuralink”这个名字的时候，他们毫不犹豫地答应了。Mohseni 说道，当时上门谈判的人并没有告诉他们，这项交易背后的金主是目前身价高达 147 亿美元的 Musk。“直到新闻爆出后，我们才发现 Neuralink 现在的合法持有人是 Musk。”现阶段，Musk 的发言人还未解释为何要购买 Neuralink 这个名字。但 Mohseni 认为，Neuralink 完美地表述了目前神经调节领域的研究方向，这或许是 Musk 对这个名字“情有独钟”的原因。另外，Mohseni 还表示，他们对于 Musk 的入局感到十分高兴，希望 Musk 能够为脑机连接领域到来“新点子”。目前，脑机连接领域中只有极少数的脑植入设备得以推向市场，我们比较熟知的应该是由医疗设备公司美力敦研发的、用于减缓帕金森患者颤抖的“深层脑部刺激器”。而其他研究则大多停留在动物实验阶段。虽然科学家们手上已经有数据表明这些技术能够在动物身上奏效，但他们还是无法确定技术在人类身上是否会有同样效果。即使未来证明技术可行，又有多少人能负担起如此昂贵的治疗费用。“正因如此，侵入式大脑技术目前的处境非常尴尬。虽然名声在外，但并没有什么实质产品。因此投资界对于这种技术大多持观望态度”Nudo 说道。不过，让不少神经科学家们感到欣慰的是，最近已经有一些企业开始关注脑机连接领域，并往这些天马行空的计划投钱了。比如，早前向大脑植入装置公司 Kernel 投入了 1 亿元的在线支付平台 Braintree，正在招募“脑机接口工程师”和脑神经专家的 Facebook…… 当然还有准备把科幻小说《Culture》中的“神经边缘”技术（Neural Lace）变为真实的 Musk。不少人期待，这位拥有着“火星殖民”、“全自动驾驶”等等“疯狂计划”并不断付诸行动的“硅谷钢铁侠”，将会给这一领域带来冲破窘境的创新想法。“不可否认，在健康人类大脑中上传和下载意识实在是有点痴人说梦，但有着百亿身家的 Musk 至少有资本去说这个梦。” Mohseni 表示。当然，Mohseni 的团队虽然没有 Musk 家底丰厚，但他们依旧行走在脑机连接这条满是荆棘的道路上。现阶段他们已经获得了来自美国军方和美国退伍军人协会的资金支持，并希望未来能够得到投资界更多的关注，以加快他们产品的商业化进程。不过在此之前，他们首先要为自己的公司起一个新名字。Nudo 打趣道：“我不会透露公司的新名字，不然有人可能会抢在我们之前注册这个商标了。”本文由百家号作者上传并发布，百家号仅提供信息发布平台。文章仅代表作者个人观点，不代表百度立场。未经作者许可，不得转载。机友之家百家号最近更新：简介:这里是志同道合的机友们的集结地作者最新文章相关文章1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
United States Patent 8937060
The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.
Inventors:
Cid-nunez, Jose Maria (Toledo, ES)
Oehlrich, Daniel (Beerse, BE)
Trabanco-suarez, Andres Avelino (Toledo, ES)
Tresadern, Gary John (Toledo, ES)
Vega Ramiro, Juan Antonio (Toledo, ES)
Macdonald, Gregor James (Beerse, BE)
Application Number:
Publication Date:
01/20/2015
Filing Date:
05/11/2010
Export Citation:
Janssen Pharmaceuticals, Inc. (Titusville, NJ, US)
Addex Pharma, SA (Geneva, CH)
Primary Class:
Other Classes:
514/233.2,
International Classes:
C07D487/04; A61K31/496; A61K31/5375; A61K31/5377; C07D241/04; C07D265/30
Field of Search:
546/119, 544/333, 544/362, 514/303, 514/210.21, 514/233.2
View Patent Images:
&&&&&&PDF help
US Patent References:
August, 2013Cid-Nunez et al.August, 2013Cid-Nunez et al.June, 2013Cid-Nunez et al.May, 2013Yan et al.8399493March, 2013Bolea et al.December, 2012Duvey et al.8299101October, 2012Cid-Nunez et al.8252937Cid-Nunez et al.July, 2012Cic-Nunez et al.July, 2012Cic-Nunez et al.May, 2012Beshore et al.February, 2012Cid-Nunez et al.December, 2011Cid-Nunez et al.November, 2011Cid-Nunez et al.October, 2011Braje et al.October, 2011Braje et al.7977325Schwede et al.7960563Johnson et al.7879837Hayashi et al.January, 2011Trabanco-Suarez et al.November, 2010Brnardic et al.November, 2010Cid-Nunez et al.September, 2010Cid-Nunez et al.September, 2010Cid-Nunez et al.July, 2010Imogai et al.April, 2010Cid-Nunez et al.April, 2010Cid-Nunez et al.March, 2010Cid-Nunez et al.March, 2010Bressi et al.December, 2009Albrechet et al.November, 2009Nagato et al.7579360Li et al.7572807Li et al.August, 2009Li et al.May, 2009Albrechet et al.May, 2009Albrechet et al.April, 2009Gaul et al.January, 2009Aaron et al.December, 2008Clayton et al.7456289Hsieh et al.November, 2008Gaul et al.September, 2008Gaul et al.7393549EbinumaNovember, 2007Imogai et al.September, 2007Imogai et al.March, 2007Herold et al.February, 2007Isaac et al.October, 2006EbinumaApril, 2006Lesage et al.November, 2005Borzilleri et al.August, 2005Himmelsbach et al.May, 2005Solow-Cordero et al.March, 2005Cheng et al.March, 2005Catalano et al.February, 2005Ford et al.January, 2005Adams et al.6835726Cushing et al.November, 2004Galley et al.October, 2004Muller et al.September, 2004Nuss et al.August, 2004Prati et al.July, 2004Dhanoa et al.July, 2004Harrington, Jr.July, 2004Yoakim et al.July, 2004Salahieh et al.June, 2004Massey et al.June, 2004Yoakim et al.May, 2004Collado Cano et al.May, 2004Lazdunski et al.May, 2004Olesen et al.April, 2004CurryApril, 2004Biediger et al.March, 2004Gharagozloo et al.March, 2004Charrier et al.March, 2004Come et al.February, 2004Eggenweiler et al.January, 2004Coleman et al.6670307Schnatierer et al.6664250Atwal et al.November, 2003Cheng et al.November, 2003Stocker et al.October, 2003Biediger et al.September, 2003Arvanitis et al.September, 2003Adam et al.6607563Ohashi et al.August, 2003Guo et al.August, 2003Hori et al.July, 2003Nakazato et al.July, 2003Jaen6586441Borroni et al.June, 2003Brotchie et al.6569863Gerritsma et al.March, 2003Wagenen et al.6509328Adam et al.6498180Collado Cano et al.December, 2002Adam et al.December, 2002Adam et al.6479436Otten et al.6472392Starck et al.6465484Bilodeau et al.October, 2002Kozikowski et al.6455528Adachi et al.September, 2002Nara et al.6433014Acher et al.6432958He6407094Adam et al.6403588Hayakawa et al.April, 2002Defeo-Jones et al.6361571Goettel et al.6358975Eliasson et al.March, 2002Jackson et al.February, 2002Li et al.January, 2002Miller et al.6333428Nakazato et al.6316498Nakazato et al.6313127Waterson et al.6284759He6262074Otten et al.6262068Atwal et al.6204292Kozikowski et al.6172058Tercero et al.6169091Cockerill et al.6162804Bilodeau et al.6143783Monn et al.6136861Chenard6133271Pamukcu et al.6130217Arnold et al.6121278Jackson et al.6110920Rochus et al.6107342Adam et al.6103475Burnett, Jr. et al.6100268Van Lommen et al.6093718Waterson et al.6054588Adam et al.6022869Faull6013672Ye et al.5958931Adam et al.5948911Pamukcu et al.5922773Lipton et al.5874432Dunlap et al.5869428Morishima et al.5859020Preuss et al.5855654Willingham et al.5814645Kanellakopulos et al.5801179Van Lommen et al.5741798Lazer et al.5723463Hofgen et al.5710274Yuan et al.5675013Hani et al.5654307Bridges et al.5650422Dunlap et al.5602145Samanen5596012Dunlap et al.5532242Cliffe5512576Desai et al.5500420Maiese5498774Mitsudera et al.5473077Monn et al.5424435Hani et al.5418243Angerbauer et al.5407948Fey et al.5378720Hlasta et al.5374513Ohzeki et al.5371074Dunlap et al.5366981Vecchietti et al.5356911Muller-Gliemann et al.5332750Mederski et al.5280026Brown et al.5260293Baker et al.5254543Hanko et al.5236917Dunlap et al.5204198Bugner et al.5175157Psiorz et al.5130442Meisel et al.5032602Fey et al.4978663Effland et al.4898654Toda et al.4866074Spada et al.4550166Moran et al.4358453Bristol et al.4256738Woitun et al.4196207Webber et al.4146716Cox et al.4066651Brittain et al.4051244Matiioda et al.2976146Salminen et al.
Foreign References:
BE841390November, 1976DIAMINO-2,4 BROMO-5 CHLORO-6 PYRIMIDINES UTILISABLES COMME MEDICAMENTS ET PROCEDE POUR LEUR PREPARATIONCA1019323October, 1977PENICILLINS, THEIR PRODUCTION, AND THEIR MEDICINAL USECA2035144July, 1991TRIAZOLOPYRIDINES HERBICIDESCN2390948December, 2000Metal combine special shuttering for concrete roof and floor constructionCN1842532October, 2006Pyrimidothiophene compoundsCNApril, 2011Synthesis method of triazol pyridine ring compoundDESeptember, 1996Verfahren zur Herstellung von 3,4-Dihydroisochinolinverbindungen und 3,4-Dihydroisochinolinium-SalzenEP0082023June, 1983THIENOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR MEDICAL USEEP0154190September, 1985Pyridones.EP0292840November, 1988Cyclic amine derivatives, medicaments containing these compounds and procedure for their preparationEP0308020March, 19895-(ARYL AND HETEROARYL)-6-(ARYL AND HETEROARYL)-1,2-DIHYDRO-2-OXO 3-PYRIDINECARBOXYLIC ACIDS AND DERIVATIVES THEREOFEP0373423June, 1989Substituted 2-pyridones and pyride-2-thiones, process for their preparation and their use in medicineEP0365486April, 1990Fibre-reactive azo dyesEP0379806August, 1990Pyrimidines and their pharmaceutical acceptable salts, and their use as medicinesEP0430385June, 1991SUBSTITUTED 1,2,4-TRIAZOLO-(4,3-A)PYRIDINES, AND SUBSTITUTED N'-(2-PYRIDYL)-HYDRAZONES, AND THEIR USE AS HERBICIDESEP0441718August, 1991Herbicidally active triazolopyridine compounds.EP0447118September, 19913-tetrazolylthiomethyl cephalosporin antibioticsEP0447891September, 1991Thieno(2,3-d)pyrimidine derivativesEP0478195September, 1991Dihydropyridazinones and pyridazinones as fungicidesEP0452002October, 1991THIENOPYRIMIDINE DERIVATIVESEP1048293April, 1992Headlice treatment compositionsEP0530702March, 19931,2-dihydro-2-oxopyridines as angiotensin II antagonists.EP0542059May, 1993Substituted biphenylpyridinones as angiotensin II antagonistsEP0547708June, 1993Saccharin derivative proteolytic enzyme inhibitorsEP0548934June, 1993Benzamide derivatives.EP0557016August, 1993Naphthalene derivatives, processes for preparing the same, and synthetic intermediates thereforEP0612746August, 1994Pyrimidines and their pharmaceutical acceptable salts and their use as medicines.EP0626378November, 1994Saccharin derivative proteolytic enzyme inhibitorsEP0728759August, 1996Heterocyclic compoundsEP0799826October, 1997Heteroaryl substituted phenylene derivatives, their preparation and their use as leukotriene receptor antagonistsEP0838458April, 1998NOVEL REAGENT FOR TETRAZOLE SYNTHESIS AND PROCESS FOR PRODUCING TETRAZOLES THEREWITHEP0856255August, 1998Pyridazinones as marine antifouling agentsEP0903343March, 1999Alpha-Substituted phenylpropionic acid derivative and medicine containing the sameEP0955301November, 19997-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptorsEP1006112June, 20003-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengersEP1203766May, 2002Carboxylic acid derivatives that inhibit the binding of integrins to their receptorsEP1277726January, 2003PROCESS FOR THE PREPARATION OF 2-HALOBENZOIC ACIDSEP1459765September, 20046-FLUOROBICYCLO 3.1.0 HEXANE DERIVATIVESEP1764099March, 2007Diaminoalcohol derivatives for the treatment of Alzheimer, malaria, HIVEP1764367March, 2007THIENOPYRIDINE DERIVATIVESEP2039687March, 2009THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSISGB1392849April, 1975PENICILLINS THEIR PRODUCTION AND THEIR MEDICINAL USEGB1502312March, 1978QUINOLONE DERIVATIVESJPAugust, 1975JPJuly, 1978JPNovember, 1982JP6110557January, 1986JP2277044November, 1990JPHOctober, 1991JP5204071August, 1993JP2124871May, 1994JP6211797August, 1994JP6211798August, 1994JP7070018March, 1995JP7101861April, 1995JPFebruary, 1998JPFebruary, 1998JPMarch, 20004-SUBSTITUTED-2-AMINOBICYCLO[3.1.0]HEXANE-2,6-DICARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITIONJPMarch, 2000ISOQUINOLINONE DERIVATIVEJPApril, 2001MEDICINE COMPRISING FLUORINE-CONTAINING AMINO ACID DERIVATIVE AS ACTIVE INGREDIENTJPJanuary, 2002BRAIN-DERIVED NEUROTROPHIC FACTOR INDUCERJPApril, 2002NEW IMIDAZOTHIAZOLE DERIVATIVEJPOctober, 2002THIENOPYRIMIDINE DERIVATIVEJPJanuary, 2003QUINAZOLINE DERIVATIVEJPAugust, 2004JPDecember, 2004HYPERTENSION THERAPEUTIC AGENT CONTAINING PYRAZOLE DERIVATIVEJPOctober, 2005JPApril, 2008JPMay, 2008RU1796625February, 19933-AMINO-7-NITRO-4-(2,3,4-TRIMETHOXYPHENYL)-2-PHENYL-1(2H) ISOQUINOLONE HAVING ANALEPTIC EFFECTRUDecember, 1999SU509578April, 1976WO/February, 1984BICYCLIC NITROGEN HETEROCYCLIC ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USESWO/March, 1984PYRIDONE COMPOUNDSWO/July, 1991PYRIDINONES USEFUL AS ANTIATHEROSCLEROTIC AGENTSWO/October, 1992USE OF HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY PAINWO/January, 1993DIBENZ[b,e]AZEPINE DERIVATIVES AND DRUGS CONTAINING THEMWO/August, 1993PYRIDONE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINESWO/September, 1994NEW COMPOUNDSWO/February, 1995[1,3,4]TRIAZOLO[1,5-a]PYRIDINES USED AS INTERMEDIATE PRODUCTS FOR THE SYNTHESIS OF DYESWO/March, 1995TYROSINE KINASE INHIBITORWO/April, 1995SUBSTITUTED PYRIDINE-2-ONES AND SUBSTITUTED PYRIDINE-2-THIONES AS BIOCIDESWO/June, 1995FIBRINOGEN RECEPTOR ANTAGONISTSWO/September, 1995NAPHTHALENE DERIVATIVES AS PROSTAGLANDIN I2 AGONISTSWO/December, 1995INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF MIGRAINE, COMPOSITION AND UTILIZATIONWO/February, 1996PYRROLIDINYL DI-CARBOXYLIC ACID DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTSWO/February, 1996GLUTAMATE RECEPTORWO/May, 1996PYRROLIDINYL DI-CARBOXYLIC ACID DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTSWO/July, 1996PROTEIN HYDROXYLATION INHIBITORS FOR FIBROPROLIFERATIVE DISORDERSWO/October, 1996HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAMEWO/November, 1996NOVEL REAGENT FOR TETRAZOLE SYNTHESIS AND PROCESS FOR PRODUCING TETRAZOLES THEREWITHWO/December, 1996METHOD OF INHIBITING VIRAL REPLICATION IN EUKARYOTIC CELLS AND OF INDUCING APOPTOSIS OF VIRALLY-INFECTED CELLSWO/March, 1997QUINOLEIN-2(1H)-ONE DERIVATIVES AS SEROTONIN ANTAGONISTSWO/March, 1997NOVEL N-AMINOALKYLFLUORENECARBOXAMIDES; A NEW CLASS OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDSWO/June, 1997FARNESYL PROTEIN TRANSFERASE INHIBITING (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVESWO/December, 19972-BENZYL-4-SULFONYL-4H-ISOQUINOLIN-1,3-DIONES AND THEIR USE AS ANTI-INFLAMMATORY AGENTSWO/December, 1997HUMAN METABOTROPIC GLUTAMATE RECEPTORWO/February, 1998METABOTROPIC GLUTAMATE RECEPTOR AGONISTSWO/March, 1998PYRAZINONES AND TRIAZINONES AND THEIR DERIVATIVES THEREOFWO/April, 1998THIENOPYRIMIDINE WITH PHOSPHODIESTERASE V INHIBITING EFFECTWO/June, 1998SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USEWO/July, 1998GEMCITABINE DERIVATIVESWO/September, 1998ISOQUINOLINONE DERIVATIVES, PROCESS FOR PREPARING THE SAME, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORSWO/November, 1998TRICYCLIC PYRIDONE ANALOGUES AS GABA-A RECEPTOR LIGANDSWO/February, 1999SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF$g(a) LEVELSWO/March, 1999AMINO-SUBSTITUTED COMPOUNDS, METHODS, AND COMPOSITIONS FOR INHIBITING PARP ACTIVITYWO/March, 1999ALKOXY-SUBSTITUTED COMPOUNDS, METHODS, AND COMPOSITIONS FOR INHI BITING PARP ACTIVITYWO/March, 1999PARP INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS OF USING SAMEWO/March, 1999PIPERIDINE DERIVATIVES AGAINST MALARIAWO/April, 1999NOVEL ANGIOGENESIS INHIBITORSWO/April, 1999INHIBITORS OF PRENYL-PROTEIN TRANSFERASEWO/May, 1999NUCLEIC ACID MOLECULES ENCODING A GLUTAMATE RECEPTORWO/June, 1999NOVEL PYRIDINE COMPOUNDSWO/June, 1999PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORSWO/July, 1999SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USEWO/July, 1999NOVEL CAMPTOTHECIN TETRACYCLIC ANALOGUES, PREPARATION, METHODS, APPLICATIONS AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEMWO/July, 1999PYRIMIDIN 3-OXIDE COMPOUNDS SUITABLE FOR THE TREATMENT OF PATHOLOGIES OF THE SKELETAL MUSCLE, IN PARTICULAR FOR THE TREATMENT OF THE HYPOKALEMIC PARALYSISWO/October, 1999N-PYRIDONYL HERBICIDESWO/October, 1999REMEDIES FOR OBESITYWO/December, 1999CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDSWO/January, 2000PHARMACEUTICAL COMPOSITIONS COMPRISING 2-QUINOLONESWO/March, 2000NOVEL ANGIOGENESIS INHIBITORSWO/April, 2000COMPOUNDSWO/June, 20003-SUBSTITUTED-4-ARYLQUINOLIN-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORSWO/September, 2000TYROSINE KINASE INHIBITORSWO/October, 2000METHOD OF TREATING NEUROLOGICAL DISORDERS WITH COMBINATIONS OF NITRIC OXIDE SYNTHASE INHIBITORS AND EXCITATORY AMINO ACID RECEPTOR MODULATORSWO/November, 2000METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTSWO/December, 2000METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASESWO/February, 20011,4-DIAZEPINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE CENTRAL NERVOUS SYSTEMWO/April, 2001TYROSINE KINASE INHIBITORSWO/May, 2001PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVESWO/May, 2001EXCITATORY AMINO ACID DERIVATIVESWO/June, 2001TRICYCLIC COMPOUNDS AND ADDITION SALTS THEREOFWO/July, 2001NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAMEWO/August, 2001PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORSWO/August, 20011,3-DISUBSTITUTED PYRROLIDINES AS ALPHA-2-ADRENOCEPTOR ANTAGONISTSWO/September, 2001USE OF PYRIDO[3,2-E]-PYRAZINONES AS INHIBITORS OF PHOSPHODIESTERASE 5 FOR TREATING ERECTILE DYSFUNCTIONWO/September, 2001DECAHYDRO-ISOQUINOLINESWO/October, 2001ISOQUINOLONE INHIBITORS OF FACTOR XaWO/November, 2001IMIDAZOPYRIDINE DERIVATIVESWO/November, 2001PROCESS FOR THE PREPARATION OF 2-HALOBENZOIC ACIDSWO/November, 2001MMP-12 INHIBITORSWO/November, 20012-PIPERIDONE COMPOUNDS FOR THE TREATMENT OF CANCERWO/December, 20011,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOFWO/January, 2002PYRIMIDINE DERIVATIVES AND THEIR USE FOR PREVENTING AND TREATING CEREBRAL ISCHAEMIAWO/February, 2002OPTICAL SHEETS CONTAINING CHOLESTERIC LIQUID CRYSTAL LAYER AND DATA RECORDING MEDIA, DATA RECORDING METHOD AND DATA DISCRIMINATING METHOD BY USING THE SAMEWO/February, 2002SUBSTITUTED TRIAZOLOPYRID(AZ)INES AS PLANT TREATMENT AGENTS (HERBICIDES)WO/February, 20022-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGSWO/March, 2002QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORSWO/April, 2002METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTSWO/July, 2002CDK4 INHIBITORSWO/September, 2002MULTILAYER PRINTED CIRCUIT BOARDWO/October, 2002IN VIVO METHODS OF DETERMINING ACTIVITY OF RECEPTOR-TYPE KINASE INHIBITORSWO/November, 2002NOVEL PYRIDINONE AND RELATED HETEROCYCLIC DERIVATIVESWO/November, 2002CCR4 ANTAGONISTSWO/December, 2002METHOD FOR TREATING GLAUCOMA VWO/December, 2002METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONSWO/December, 20021,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDSWO/December, 2002NOVEL ISOXAZOLOPYRIDONE DERIVATIVES AND USE THEREOFWO/February, 2003PYRIDINONE AND PYRIDAZINONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTSWO/April, 2003CHEMICAL COMPOUNDSWO/May, 2003SUBSTITUTED INDOLIZINE-LIKE COMPOUNDS AND METHODS OF USEWO/May, 2003PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOFWO/May, 2003COMPOSITIONS COMPRISING AT LEAST ONE OXONOL DYE AND AT LEAST ONE METAL COMPLEXWO/June, 2003PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USESWO/June, 2003HIGH CAPACITY CATCH BASIN FILTRATION SYSTEM WITH ADJUSTABLE DEFLECTOR RINGWO/June, 2003COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASEWO/July, 2003MODULATORS OF LXRWO/July, 2003METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTORWO/July, 20032-HETEROARYLCARBOXYLIC ACID AMIDESWO/July, 2003N-ALKYLSULFONYL-SUBSTITUTED AMIDE DERIVATIVESWO/August, 2003SCHWANN CELL AND PHOSPHODIESTERASE INHIBITORS BASED THERAPYWO/August, 2003SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASEWO/August, 2003JNK INHIBITORWO/August, 2003FURANO- AND THIENOPYRIMIDINES AS NEUROKINASE INHIBITORSWO/August, 2003THIOIBOTENIC ACID AND DERIVATIVES THEREOFWO/September, 2003MONOCYCLIC AROYLPYRIDINONES AS ANTIINFLAMMATORY AGENTSWO/October, 2003SUBSTITUTED 2,3-DIPHENYL PYRIDINESWO/October, 2003THERAPY FOR PSYCHOSES COMBINING AN ATYPICAL ANTIPSYCHOTIC AND AN MGLU2/3 RECEPTOR AGONISTWO/November, 2003TYROSINE KINASE INHIBITORSWO/December, 2003SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USEWO/December, 2003PRODRUGS OF EXCITATORY AMINO ACIDSWO/December, 20032-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND/OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONSWO/December, 2003ARYLAMINE SUBSTUTUTED BICYCLIC HETEROAROMATIC COMPOUNDS AS P38 KINASE INHIBITORSWO/January, 20043-&grave (HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORSWO/February, 2004PYRIDAZINYLPIPERAZINE DERIVATIVES FOR TREATING PAINWO/February, 2004PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATESWO/February, 2004BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORSWO/March, 2004PHOSPHADIDYLINOSITOL 3,5-BIPHOSPHATE INHIBITORS AS ANTI-VIRAL AGENTSWO/March, 2004ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORSWO/March, 2004HETEROCYCLIC AROMATIC COMPOUNDS USEFUL AS GROWTH HORMONE SECRETAGOGUESWO/March, 2004COMBINATION THERAPY FOR TREATMENT OF FIBROTIC DISORDERSWO/March, 2004MGLU RECEPTORS ANTAGONISTS FOR TREATING DISORDERS ASSOCIATED WITH MGLU RECEPTORS INCLUDING ADDICTION AND DEPRESSIONWO/April, 2004PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSIONWO/April, 2004NOVEL HERBICIDES, USAGE THEREOF, NOVEL THIENOPYRIMIDINE DERIVATIVES, INTERMEDIATES OF THE SAME, AND PROCESS FOR PRODUCTION THEREOFWO/May, 2004ANTI-INFECTIVE AGENTSWO/May, 2004N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES AS ANTIMICROBIALSWO/July, 2004JNK INHIBITORSWO/August, 2004SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTSWO/August, 20041,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PRPPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIAWO/August, 2004SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACTWO/September, 2004PHARMACEUTICAL PREPARATIONS CONTAINING THIAZOLIDINEDIONES FOR THE TREATMENT OR PREVENTION OF IP-10 MEDIATED DISEASESWO/September, 2004PHENYL- AND PYRIDYLPIPERIDINE-DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISMWO/September, 20042,5- AND 2,6-SUBSTITUTED TETRAHYDROISOQUINOLINES FOR USE AS 5-HT6 MODULATORSWO/September, 2004PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDSWO/October, 2004INHIBITORS OF FUNGAL INVASIONWO/October, 2004SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORSWO/October, 2004MUTANT FORMS OF GLUTAMATE RECEPTORS MGLUR2 AND MGLUR3WO/January, 2005COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTORWO/January, 2005METHOD OF DIAGNOSIS AND TREATMENT FOR ASTHMA BASED ON HAPLOTYPE ASSOCIATIONWO/March, 2005PYRIMIDOTHIOPHENE COMPOUNDSWO/March, 2005DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAINWO/May, 2005METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUESWO/September, 2005TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITSWO/October, 2005KERATIN DYEING COMPOSITIONS BICYCLIC 5-6 HETEROAROMATIC DYEING COMPOUNDS WITH ONE RING NITROGEN JUNCTIONWO/October, 2005THIENOPYRIDINE DERIVATIVESWO/December, 2005ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORSWO/February, 2006CHEMICAL COMPOSITION FOR THE LIQUEFACTION AND DISSOLUTION OF ASPHALTENE AND PARAFFIN SLUDGES IN PETROLEUM CRUDE OILSWO/February, 2006HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORSWO/February, 2006INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORSWO/February, 2006INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOFWO/February, 2006TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATIONWO/February, 2006ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORSWO/March, 2006NOVEL THIENO-PYRIDINE AND THIENO-PYRIMIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORSWO/March, 2006NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORSWO/March, 2006SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDSWO/May, 2006HETEROCYCLIC INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORSWO/June, 2006POTENTIATORS OF GLUTAMATE RECEPTORSWO/June, 2006POTENTIATORS OF GLUTAMATE RECEPTORSWO/July, 2006ANTI-TUMOR COMPOUNDSWO/July, 2006PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERSWO/August, 2006BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORSWO/September, 2006ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTSWO/October, 2006AGENT FOR TREATING INVOLUNTARY MOVEMENTWO/December, 2006NOVEL FUROPYRIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE DERIVATIVE, AND USE OF THE DERIVATIVE OR COMPOSITIONWO/February, 2007METABOTROPIC GLUTAMATE-RECEPTOR-POTENTIATING ISOINDOLONESWO/February, 2007SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORSWO/March, 2007IMPROVED BIODIESEL FUEL, ADDITIVES, AND LUBBRICANTSWO/March, 20075-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSIONWO/April, 2007OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTSWO/May, 2007N4-PHENYL-QUINAZ0LINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASESWO/July, 20075-PHENYL-3-BENZYL-0XAZ0LIDIN-2-0NE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERSWO/August, 2007METABOTROPIC GLUTAMATE RECEPTOR-POTENTIATING ?SOINDOLONESWO/September, 2007THIAZOLONES FOR USE AS PI3 KINASE INHIBITORSWO/September, 20071,4 -DI SUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPT0R MODULATORSWO/October, 2007NOVEL BI-ARYL AMINESWO/November, 2007TRYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALSWO/November, 2007BENZIMIDAZOLYL COMPOUNDSWO/November, 2007AZABENZIMIDAZOLYL COMPOUNDS AS MGLUR2 POTENTIATORSWO/January, 2008TRIAZOLOPYRIDINE DERIVATIVES AS HERBICIDESWO/January, 2008FUSED HETEROCYCLIC DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTORWO/January, 2008AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTORWO/March, 2008SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORSWO/April, 2008IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROFWO/May, 2008SMALL-MOLECULE BOTULINUM TOXIN INHIBITORSWO/May, 2008HETEROCYCLIC COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-I, AND/OR NP-KAPPA-B ACTIVITYWO/June, 2008NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORSWO/July, 2008BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORSWO/July, 2008TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORSWO/August, 2008AZA-ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 613WO/September, 2008NEW 3-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-7-YL)BENZAMIDE DERIVATIVESWO/September, 20083-CYANO-4-(4-PHENYL-PIPERIDIN-1-YL)-PYRIDIN-2-ONE DERIVATIVESWO/September, 20081,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2 -RECEPTOR MODULATORSWO/September, 20083-CYANO-4-(4-TETRAHYDROPYRAN-PHENYL)-PYRIDIN-2-ONE DERIVATIVESWO/September, 2008SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOFWO/October, 2008METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORSWO/October, 2008HYDRAZIDES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 681WO/December, 2008HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR)WO/December, 2008METABOTROPIC GLUTAMATE RECEPTOR OXADIAZOLE LIGANDS AND THEIR USE AS POTENTIATORS - 841WO/December, 2008OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842WO/January, 2009N-BENZYL OXAZOLIDINONES AND RELATED HETEROCYCLEIC COMPOUNDS AS POTENTIATORS OF GLUTAMATE RECEPTORSWO/March, 20091,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONESWO/March, 20091,3-DISUBSTITUTED-4-PHENYL-1 H-PYRIDIN-2-ONESWO/March, 20091',3'-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1'H-[1, 4'] BIPYRIDINYL-2'-ONESWO/April, 2009TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORSWO/April, 2009DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISTIC ACTIVITY ON MELANIN-CONCENTRATING HORMONE RECEPTORWO/May, 2009IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORSWO/July, 2009FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AS C-MET INHIBITORSWO/July, 20093,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVESWO/September, 2009SUBSTITUTED DIHYDRO, TRIHYDRO AND TETRAHYDRO CYCLOALKYLOXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF AS ALLOSTERIC MODULATORS OF MGLURWO/October, 2009DEVIATION DEVICE FOR A BEAM OF AN ELECTROMAGNETIC WAVEWO/November, 2009OXAZOLOBENZIMIDAZOLE DERIVATIVESWO/November, 2009OXAZOLOBENZIMIDAZOLE DERIVATIVESWO/December, 2009ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORSWO/January, 2010IMIDAZOLE CARBOXAMIDESWO/February, 2010TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORSWO/February, 2010TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORSWO/April, 2010INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORSWO/June, 2010METHOD FOR APPROXIMATING THE TIME CURVE OF TRAFFIC DATAWO/July, 2010INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORSWO/August, 2010CYCLIC INHIBITORS OF 11 ?-HYDROXYSTEROID DEHYDROGENASE 1WO/October, 2010SUBSTITUTED TRIAZOLOPYRIDINES AND ANALOGS THEREOFWO/October, 2010AMINOBENZOTRIAZOLE DERIVATIVESWO/November, 20103-AZABICYCLO[3.1.0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORSWO/November, 20101,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORSWO/November, 20107-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORSWO/November, 20101,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERSWO/December, 2010BIARYL BENZOTRIAZOLE DERIVATIVESWO/February, 2011ETHER BENZOTRIAZOLE DERIVATIVESWO/March, 2011IMIDAZOPYRIDIN-2-ONE DERIVATIVESWO/March, 2011SUBSTITUTED PARA-BIPHENYLOXYMETHYL DIHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOFWO/March, 2011SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOFWO/March, 2011SUBSTITUTED PHENOXYMETHYL DIHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOFWO/May, 2011HETEROCYCLIC DERIVATIVESWO/September, 2011POSITIVE ALLOSTERIC MODULATORS OF MGLUR2WO/September, 2011POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURSWO/November, 2011POLYMORPHS OF A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORWO/November, 2011SUBSTITUTED 1,3-BENZOTHIAZOL-2(3H)-ONES AND [1,3]THIAZOLO[5,4-B]PYRIDIN-2(1H)-ONES AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2WO/December, 2011POSITIVE ALLOSTERIC MODULATORS OF MGLUR2WO/February, 2012POSITIVE ALLOSTERIC MODULATORS OF MGLUR2WO/May, 20121,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORSWO/May, 20121,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORSWO/May, 2012RADIOLABELLED mGLuR2 PET LIGANDSWO/May, 20121,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORSWO/November, 2012AMINOMETHYL BIARYL BENZOTRIAZOLE DERIVATIVESWO/November, 2012ALKYNE BENZOTRIAZOLE DERIVATIVESWO/November, 2012HYDROXYMETHYL BIARYL BENZOTRIAZOLE DERIVATIVES
Other References:
Celanire et al., Annual Reports in Medicinal Chemistry -88.
McElvain et al. “Piperidine Derivatives. XXX. 1,4-Dialkyl-4-arylpiperidines”, J. Am. Chem. Soc, 15-3923.
Moldrich et al., Glutamate metabotropic receptors as targets for drug therapy in epilepsy, European Journal of Pharmacology 476 (.
Mongin et al. “Advances in the directed metallation of azines and diazines (pyridines, pyrimidines, pyrazines, pyridazines, quinolines, benzodiazines and carbolines). Part 1: Metallation of Pyridines, quinolines and carbolines”, Tetrahedron, ), .
Moore et al. “Cycloadditions of Cyanoketenes to Cinnamylideneamines and Benzylideneamines. Synthetic Scope, Stereochemistry, and Mechanism”, Journal Org. Chem. 31-4238.
Morrill et al., “Synthesis of 4-Arylpiperidines from 1-Benzyl-4piperidone: Application of the Sharpiro Reaction and Alkenylsilane Cross-coupling,” Organic Letters, 2007, vol. 9, pp. .
Mutel et al., “Characterization of (2S,2′R,3′R)-2-(2′,3′[3H]-Dicarboxycyclopropyl)glycine Binding in Rat Brain,” J Neurochemistry, 71(6), -2564.
Mutel, “Therapeutic potential of non-competitive, subtype-selective metabotropic glutamate receptor ligands”, Expert Opin. Ther. Patents (2002), 12 (12) p. .
Nakamura et al., “An Efficient Synthesis of Platelet-Activating Factor (PAF) J′IJ I-Qalkyl-2-~-(3-Isoxazolyl)-SN—Glycero-3-Phosphocholine, A New PAF Agonist. Utilization of the 3-Isoxazolyloxy Group as a Protected Hydroxyl.” Tetrahedron Letters, 1990, vol. 31, 699-702.
Nakanishi, et al., Glutamate receptors: brain function and signal transduction, Brain Research Reviews 26 (5.
Nakano et al. “1-Alkyl-3-phenylpyridinium 1-Alkyl-2(1H)-pyridone 3-Phenyl 5-Phenyl”, Annual Report of Tohoku College of Pharmacy, 5-148.
Nell et al., “Preparation of 4-amino-3,5-dicyano-2-thiopyridines as cardiovascular agents”, CA149:3).
Ohishi et al., “Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: an immunohistochemical study with a monoclonal antibody,” Neuroscience Research 30 (.
Ojima et al., “Hydroformation of Fluoro Olefins, RfCH═CH2, Catalyzed by Group VIII Transition-Metal Catalysts. Crucial Factors for Extremly High Regioselectivity”, Journal of American Chemical Society, , .
Pin et al., “New perspectives for the development of selective metabotropic glutamate receptor ligands,” European J of Pharmacology, , 277-294.
Pinkerton, et al., Phenyl-tetrazolyl Acetophenones: Discovery of Positive Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor, J. Med. Chem 95-4599.
Poisik, et al., Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus, Neuropharmacology 49 (.
Potts et al. “1,2,4-Triazoles. XII. Derivatives of the s-Triazolo[4,3-a]pyridine Ring System”, Journal of Organic Chemistry, 0.
Potts et al. “1,2,4-Trizoles. XXV. The Effect of Pyridine Substitution on the Isomerization of s-Triazolo [4,3-a] pyridines into s-Triazolo [1,5-a] pyridines (1)”, J. Heterocycl. Chem., 19-1027.
Prager et al. “The Synthesis of Peroline, 6-(3,4-Dimethoxyphenyl)-5-hydroxy-5,6-dihydrobenzo[c][2,7]naphthyridin-4(3H)-one”, Aust. J. Chem., 41-1453.
Rani et al. “Thiazoline Analogues of Epiderstatin, New Inhibitiors of Cell Cycle of TsFT-210 Cells”, Journal of Antibiotics, ), .
Renslo et al., “Synthesis of Aza-, Oxa-, and Thiabicyclo[3.1.0]hexane Heterocycles from a Common Synthetic Intermediate,” Organic Letters, 2005, vol. 7, No. 13, , American Chemical Society, USA.
Roma et al., “1,8-Naphthyridines VII. New substituted 5-amino[I,2,4]triazolo[4,3-a] [1 ,8]naphthyridine-6-carboxamides and their isosteric analogues, exhibiting notable anti-inflammatory and/or analgesic activities, but no acute gastrolesivity”, European Journal of Medical Chemistry. 65-1680.
Rosowsky et al. “2,4-Diaminothieno[2,3-d]pyrimidines as Antifolates and Antimalarials. 3. synthesis of 5,6-Disubstituted Derivatives and Related Tetracyclic Analogs”, Journal of Medicinal Chemistry, ,191-194.
Ryndina, et al., Torp-Ziegler Cyclization in the Synthesis of 3-Amino-4-Cyanopyrrole Derivatives, Chemistry of Heterocyclic Compounds, vol. 36, No. 12, 2000, pp. 1409-20.
Schaffhauser et al., “In Vitro Binding Characteristics of a New Selective Group II Metabotropic Glutamate Receptor Radioligand, [3H]LY354740, in Rat Brain,” Mol Pharmacology, 53, 228-233, 1998.
Schaffhauser et al., “Pharmacological Characterization and Identification of Amino Acids Involved in the Positive Modulation of Metabotropic Glutamate Receptor Subtype 2,” Mol. Pharmacol 64:798-810, 2003, vol. 64, No. 4.
Schiefer et al. “The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease,” Brain Research ) 246-254.
Schoepp et al, “Pharmacological agents acting at subtypes of metabotropic glutamate receptors,” Neuropharmacology 38 (-1476.
Schoepp et al., “Preclinical Pharmacology of mGlu2/3 Receptor Agonists: Novel Agents for Schizophrenia?”, CNS & Neurological Disorders, 5-225.
Senda et al. “Ring Transformation of Uracils to 2-Pyridones. Hydrolysis of 6-(Dimethylaminovinyl) Uracils” Heterocycles, , 1-6.
Shiba et al. “Synthesis and binding affinities of methylvesamicol analogs for the acetylcholine transporter and sigma receptor”, Bioorganic and Medicinal Chemistry, 20-2626.
Simmons et al., “Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats,” Pharmacology, Biochemistry and Behavior 73 (7.
SIPO Office Action Jun. 30, 2010.
Stewart et al. “Discovery of Inhibitors of Cell Adhesion Molecule Expression in Human Endothelial Cell. 1. Selective Inhibition of ICAM-1 and E-Selectin Expression”, J Med Chem, 8-1002.
Turck et al. “Advances in the directed metallation of azines and diazines (pyridines, pyrimidines, pyrazines, pyridazines, quinolines, benzodiazines and carbolines). Part 2: Metallation of pyrimidines, pyrazines, pyridazines and benzodiazines”, Tetrahedron, ), .
Tutonda et al. “Diels-Alder Reactions of the Heterodiene System in 2(1H)-Pyrazinones”, Tetrahedron Letters, , .
VanAllan et al. “Reactions of Some 4-Methylene-4H-pyran Derivatives with Primary and Secondary Amines”, Journal of Heterocyclic Chemistry, 5-507.
Vilsmaier et al., “Diastereoselective Syntheses of N-Protected Derivatives of Ia,5a,6fi-6-Amino-3-azabicyclo [3.101] A Route to Trovafloxacin 6fI-Diastereomer,” Synthesis, 4.
Vippagunta et al., Crystalline Solids, Adv. Drug Deily. Rev., 2001, 48, pp. 3-26.
Wang et al. “A simple and efficient automatable one step synthesis of triazolopyridines form carboxylic acids”, Tetrahedron Letters, 37-2240.
Watanbe et al. “Pd/P(t-Bu)3-Catalyzed Synthesis of Aromatic Amines”, Journal of TOSOH Research, 1999, vol. 43, 38-50.
Wenner et al, “Derivatives of 2-Pyridone”, Journal of Organic Chemistry, 1946, vol. 11, pp. 751-759.
West Anthony R. Solid State Chemistry and Its Applications, Wiley, New York, 1988 pp. 358 & 365.
Yalyaheva et al.,Chemical Abstract, Heterocycles, p. 687, vol. 107, 1987.
Acta Chimica Slovencia, 2005, vol. 52, No. 4, pp. 391-397.
Al-Orman et al. “Studies with Polyfunctionally Substituted Heteroaromatics: New Routes for the Synthesis of Polyfunctionally Substituted Pyridines and 1,2,4-Triazolo[1,5-a]pyridines”, Heteratom. Chemistry, vol. 6, No. 6, 1.
Azimov et al. Chemical Abstracts, 1986, abstract No. 78798, vol. 105 No. 10.
Azume et al., “Synthesis and reactions of 4-choloro-1, 2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile”, CA139:03).
Boatman et al., “Alkylations at the Methyl or alpha-Methylene Group of 6- or 4-Alkyl-3-cyano-2(1)-pyridones through Dianions”, Journal of Organic Chemistry, 1965, vol. 30 Pt 11, pp. .
Bohme et al., “Darstellng und Umsetzungen von 3-Arylamino-2-halogencrotononitilen”, Chem. Ber., , .
Bradley et al. “Activation of Group II Metabotropic Glutamate Receptors Inhibits Synaptic Excitation of the Subsantia Nigra Pars Reticulata,” J. of Neuroscience, May 1, ):.
Braish et al., “Construction of the (1x,5x,6x)-6-Amino-3-azabicyclo[3.1.0]hexane Ring System,” Synlett, -1102.
Brighty et al., “Synthesis of (1x,5x,6x)-6-Amino-3-azabicyclo[3.1.0]hexane, a Novel Achiral Diamine,” Synlett, -1099.
CA Office Action Apr. 23, 2010.
Cartmell et al. “Regulation of Neurotransmitter Release by Metabotropic Glutamate Receptors”, J. Neurochem., p. 889-907, vol. 75, No. 3, 2000.
Duong et al. “A Biogenetic Like Synthesis of Perloline, 6-(3,4-Dimethoxyphenyl)-5-hydroxy-5,6-dihydrobenzo[c][2,7]naphthyridin-4(3H)-one”, Aust. J. Chem., 31-1440.
Feinberg et al, “The selective group mGlu2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat,” Pharmacology, Biochemistry and Behavior 73 (4.
Galici et al., A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors Has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic Activity, J of Pharmacology and Experimental Therapeutics, p. , vol. 315, No. 3.
Govek et al. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): Efficacy in an animal model for schizophrenia, Bioorg. Med. Chem Lett. 15 (-4072.
Grillon, et al., Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans, Psychopharmacology (6-454.
Hamaguchi et al., “Effects of Hetero Atom Substituents in the decomposition of Pyrazolines: Abnormal Behavior of Methoxy Group Compared with Arylthio of Arylseleno Group.”, Heterocycles, 1986, vol. 24, .
Hanfeld et al. “Synthese von 3-Cyan-6-methyl-4-pyridyl- und 3-cyan-4-methyl-6-pyridyl-pyrid-2(1H)-onen und -thionen”, Pharmazie 43 (1988), H.11, 762-764.
Haper, “Agonist-Stimulated [35S]GTPyS Binding,” Current Protocols in Pharmacology, 1998, Unit 2.6, 1-10.
Harriman et al. “Synthesis of 4-Substituted 4-Arylpiperidines”, Tetrahedron Letters, 53-8856.
Helton et al. “Anxiolytic and Side-Effect Profile fo LY354740: A Potent, Highly Selective, Orally Active Agonist for Group II Metobotropic Glutamate Receptors”, Journal of Phamacology and Experimental Therapeutics, , 2, 651-660.
Holden, “Excited by Glutamate”, Science, p. , vol. 300, Jun. 20, 2003.
Hughes, “Progress in the Mitsunobu Reaction. A Review,” Organic Preparations and Procedures International, 4.
Hughes, “The Mitsunobu Reaction”, Organinc Reactions, 1992, vol. 42, 335-656.
International Search Report dated Oct. 26, 2009 for international application No. PCT/EP.
International Search Report for International Application No. PCT/EP dated Sep. 7, 2007.
Jain et al. “A One-Step Preparation of Functionalized 3-Cyano-2-Pyridones”, Tetrahedron Letters, , .
Johnson et al. Discovery of Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor: Synthesis and Subtype Selectivity of N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluorethylsulfonyl)pyrid-3-ylmethyl-amine, J. Med. Chem. 89-3192.
Johnson et al. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists, Biochemical Society Transactions (2004) vol. 32, part 5, 881-887.
Johnson et al., Selective, Non-Amino Acid Allosteric mGlu2 Receptor Potentiators Inhibit Dural Plasma Protein E A Potential Role in the Treatment of Migraine, Abstracts/Neuropharmacology 43 (.
Kambe et al “A Convenient Method for the Preparation of 2-Pyridone Derivatives”, 1977, vol. 12, pp. 841-842.
Kellner et al., Effects of metabotropic glutamate2/3 receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in health humans: preliminary results, Psychopharmacology (: 310-315.
Khimia Geterotsiklicheskikh Soedinenii, 1985, vol. 5, PT 9.
Khimia Geterotsiklicheskikh Soedinenii, 1986, vol. 1986, PT 8, .
Kilama et al. “A New Synthstic Approach to the C-D Ring Portion of Streptonigrin Analogues” Journal of Heterocyclic Chemistry, 37-1440.
Kiselyov et al., “A one pot synthesis of polysubstituted inidazo[1,2-a]pyridines”, Tetrahedron Letters, 41-2944.
Kitano et al., “Synthesis and antifouling activity of 3-isocyanotheonellin and its analogues”, Jour Chem Soc Perkin Trans, -2255, The Royal Society of Chemistry.
Klemm et al. “Chemistry of Thienopyridines. VIII. Substitution Products Derived from Thieno[2,3-b] pyridine 7-Oxide (1)”, Journal of Heterocyclic Chemistry, ), 81-89.
Lan et al., Activation of Metabotropic Glutamate Receptor-1 Accelerates NMDA Receptor Trafficking, Abstracts/Neuropharmacology 43 (.
Larock, “Comprehensive Organic Transformations”, VCH Publishers, 6.
Lee et al., “Benzylic Bromination of Alkylbenzenes with Sodium Bromate-Bromotrimethylsilane”, Bull. Korean Chem. Soc, 1995, vol. 16, pp. 371-374.
Malames et al. “N-Substituted Spirosuccinimide, Spiropyridazine, Spiroazetidine, and Acetic Acid Aidose Reductase Inhibitiors Derived From Isoquinoline-1,3-dinoes. 2”, J Med Chem., ), .
“Benneyworth et al., “A Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 2 Blocks a Hallucinogenic Drug Model of Psychosis,” Mol. Pharmacol., 7-484.”
Braga et al. “Making Crystals from Crystals: A Green Route to Crystal Engineering and Polymorphism” Chem. Commun. -3645.
Chrostopoulos., “Allosteric Binding Sites on Cell-Sturcture Receptors: Novel Targets for Drug Discovery”, Nature Rev., Mar. 8-210.
“Eisa et al., “Synthesis of some novel tetrazole derivatives as potential antimicrobial agents,” Pakistan J. of Scientific and Industrial Res, vol. 33, 1990, p. 417-420”.
Galici et al. “Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in Mice”, Journal of Phamacology and Experimental Therapeutics, ,173-185.
International Search Report dated Jul. 2, 2008 for application No. PCT/EP08/52767.
International Search Report dated Jun. 10, 2008 for application No. PCT/EP08/52766.
International Search Report dated Jun. 10, 2008 for application No. PCT/EP08/52768.
Johnson et al. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s), Psychopharmacology (: 271-283.
Seddon “Pseudopolymorph: A Polemic” Crystal Growth & Design, 4(6), .
Wikipedia, “Allosteric Regulation”, .
Abi-Saab et al., “The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls”, Pharmacopschiatry, 31, 9.
Abshire et al., “Injection of L-Allylglycine Into the Posterior Hypothalamus in Rats Causes Decreases in Local GABA Which Correlate with Increases in Heart Rate”, Neuropharmacology, ), .
Adam, “Symptomatic Treatment of Huntington Disease”, Neurotherapeutics: the Journal of the American Society for Experimental Neurotherapeutics, Apr. 1-197.
Adams et al., “Effect of Clozapine, Haloperidol, or M100907 on Phencyclidine-Activated Glutamate Efflux in the Prefrontal Cortex”, Biol. Psychiatry ), 750-757.
Adams, “A Long-Term, Phase 2, Multicenter, Randomized, Open-Label, Comparative Safety Study of Pomaglumetad Methionil (LY2140023 Monohydrate) Versus Atypical Antipsychotic Standard of Care in Patients with Schizophrenia”, BMC Psychiatry ), 1-9.
Addex Partner Completes ADX71149 Phase I Program, Press release Aug. 25, 2010, http://www.addextherapeutics.com/investors/press-releases/news-details/?tx—ttnews%5Btt—news%5D%20=103&cHash=91fade38b1d3dcb1a9281, retrieved on Aug. 22, 2013.
Addex Partner Doses First Patient in Phase 2 Clinical Study of ADX71149 for the Treatment of Major Depressive Disorder Patients with Anxiety Symptoms, Press Release Sep. 17, 2012, http://www.addextherapeutics.com/investors/press-releases/news-details/?tx—ttnews%5Btt—news%5D%20=214&cHash=12a9cc5ffefdb63c27d5b87a673f74eb, retrieved on Aug. 22, 2013.
Addex Partner to Initiate Phase 2 Clinical Trial of ADX71149 for the Treatment of Major Depressive Disorder with Anxiety Symptoms, Press Release Jun. 5, 2012 http://www.addextherapeutics.com/investors/press-releases/news-details/?tx—ttnews%5Btt—news%5D%20=204&cHash=d0bbb2b5f32c, retrieved on Aug. 22, 2013.
Addex Reports Top-line Data from a Successful Phase 2a Clinical Study with ADX71149 in Schizophrenia Patients, Press Release Nov. 5, 2012, http://www.addextherapeutics.com/investors/press-releases/news-details/?tx—ttnews%5Btt—news%5D%20=225&cHash=9e5e13cb5f8ac786ce7453 retrieved on Aug. 22, 2013.
Addington et al., “A depression rating scale for schizophrenics”, Schizophr Res. ), 247-251.
Ader et al., “Effects of Chlorpromazine on the Acquisition and Extinction of an Avoidance Response in the Rat”, J. Pharmacol. Exp. Ther., , 144-148.
Agami et al., “An Efficient Synthesis of Polysubstituted 3-Halo-2(1H)-Pyridinones.” Synthesis, .
Agari et al., “Intrapallidal Metabotropic Glutamate Receptor Activation in a Rat Model of Parkinson's Disease: Behavioral and Histological Analyses”, Brain Res., , 189-196.
Aghajanian et al., “Serotonin model of schizophrenia: Emerging role of glutamate Mechanisms”, Brain Research Reviews, 2-312.
Aghajanian, “Modeling ‘Psychosis’ in Vitro by Inducing Disordered Neuronal Network Activity in Cortical Brain Slices”, Psychopharmacology ), 575-585.
Agid et al., “How Can Drug Discovery for Psychiatric Disorders Be Improved?” Nature Reviews Drug Discovery, 9-201.
Ago et al., “Activation of Metabotropic Glutamate 2/3 Receptors Attenuates Methamphetamine-Induced Hyperlocomotion and Increase in Prefrontal Serotonergic Neurotransmission”, Psychopharmacology, , 443-452.
Ahnaou et al., “Modulation of Group II Metabotropic Glutamate Receptor (Mglu2) Elicits Common Changes in Rat and Mice Sleep-Wake Architecture”, European Journal of Pharmacology, , 62-72.
Ainslie et al., “Practical Drug Evaluation Method”, Arch Gen Psychiat, 8-373.
Alagarsamy et al., “Coordinate Regulation of Metabotropic Glutamate Receptors”, Current Opinion in Neurobiology, ), 357-362.
Albasanz et al., “Internalization of Metabotropic Glutamate Receptor in C6 Cells Through Clathrin-Coated Vesicles”, Molecular Brain Research, -66.
Alderson et al., “Purification and Characterization of a Soluble Cyclic Nucleotide-Independent Ca2+-Calmodulin-Sensitive Protein Kinase from Rat Brain”, J. Neurochem., 4-603.
Aleppo et al., “Metabotropic Glutamate Receptors and Neuronal Toxicity”, Advances in Experimental Medicine & Biology, , 137-145.
Alexander et al., “Metabotropic Glutamate Receptors as a Strategic Target for the Treatment of Epilepsy”, Epilepsy Res., ), 1-22.
Allen et al., “Group II Metabotropic Glutamate Receptor Activation Attenuates Traumatic Neuronal Injury and Improves Neurological Recovery After Traumatic Brain Injury”, J Pharmacol. Exp. Ther., ), 112-120.
Alley et al., “Memantine Lowers Amyloid-Beta Peptide Levels in Neuronal Cultures and in APP/PS1 Transgenic Mice”, J Neurosci Res, 3-154.
Al-Shamma et al., “Nelotanserin, a Novel Selective Human 5-Hydroxytryptamine2a Inverse Agonist for the Treatment of Insomnia”, J Pharmacol Exp Ther, , 281-290.
Altamura et al., “Designing Outcome Studies to Determine Efficacy and Safety of Antipsychotics for ‘Real World’ Treatment of Schizophrenia”, Int J Neuropsychopharmacol, ):971-973.
Altamura et al., “Plasma and Platelet Exctitatory Amino Acids in Psychiatric Disorders”, Am J Psychiatry, ), .
Altamura et al., “Plasma Concentrations of Excitatory Amino Acids Serine, Glycine, Taurine and Histidine in Major Depression”, Eur Neuropsychopharmacol, 1995; 5(Suppl), 71-75.
Amiri et al., “A Role for Leu118 of Loop E in Agonist Binding to the α7 Nicotinic Acetylcholine Receptor” Mol Pharmacol, 59-1667.
Amitai et al., “Effects of Metabotropic Glutamate Receptor 2/3 Agonism and Antagonism on Schizophrenia-Like Cognitive Deficits Induced by Phencyclidine in Rats”, European Journal of Pharmacology, , 67-80.
Andreescu et al., “Comorbid Anxiety and Depression: Bête Noire or Quick Fix?”, British Journal of Psychiatry 9-181.
Andreescu et al., “Effect of Comorbid Anxiety on Treatment Response and Relapse Risk in Late-Life Depression: Controlled Study”, the British Journal of Psychiatry, , 344-349.
Andreescu et al., “The Default Mode Network in Late-Life Anxious Depression”, Am J Geriatr Psychiatry, Nov. ), 5 pages.
Andres et al., “2-(Dimethylaminomethyl)-Tetrahydroisoxazolopyridobenzazepine Derivatives. Synthesis of a New 5-HT2C Antagonist with Potential Anxiolytic Properties”, Bioorganic & Medicinal Chemistry Letters, 73-3577.
Andres et al., “Synthesis, Evaluation, and Radiolabeling of New Potent Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2 as Potential Tracers for Positron Emission Tomography Imaging”, J Med Chem, 85-8699.
Angenstein et al., “Activation of Metabotropic Glutamate Receptors Increases Endogenous Protein Kinase C Substrate Phosphorylation in Adult Hippocampal Slices”, Brain Research, -2), 46-54.
Angers et al., “Dimerization: An Emerging Concept for G Protein-Coupled Receptor Ontogeny and Function”, Annu. Rev. Pharmacol. Toxicol., 9-435.
Antuono, “Decreased Glutamate 1 Glutamine in Alzheimer's Disease Detected in Vivo with 1H-MRS at 0.5 T”, Neurology, -742.
Anwyl “Metabotropic Glutamate Receptor-Dependent Long-Term Potentiation”, Neuropharmacology, 5-740.
Anwyl “Metabotropic Glutamate Receptors: Electrophysiological Properties and Role in Plasticity”, Brain Res. Brain Res., -120.
Aparicio-Legarza et al., “Deficits of [3h]D-Aspartate Binding to Glutamate Uptake Sites in Striatal and Accumbens Tissue in Patients with Schizophrenia”, Neuroscience Letters, ), 13-16.
Aparicio-Legarza et al., “Increased Density of Glutamate/N-Methyl-D-Aspartate Receptors in Putamen From Schizophrenic Patients”, Neuroscience Letters,-3), 143-146.
Armstrong et al., “Characterization of Competitive Inhibitors for the Transferase Activity of Pseudomonas Aeruginosa Exotoxin A”, Journal of Enzyme Inhibition and Medicinal Chemistry, ), 235-246.
Arnt, “Differential Effects of Classical and Newer Antipsychotics on the Hypermotility Induced by Two Dose Levels of D-Amphetamine”, European Journal of Pharmacology, , 55-62.
Arnt, “Pharmacological Specificity of Conditioned Avoidance Response Inhibition in Rats: Inhibition by Neuroleptics and Correlation to Dopamine Receptor Blockade”, Acta Pharmacol. Toxicol., 1-329.
Aronica et al., “Metabotropic Glutamate Receptors in Cultured Cerebellar Granule Cells: Developmental Profile”, Journal of Neurochemistry, ), 559-565.
Aronica et al., “Pharmacological Characterization of Metabotropic Glutamate Receptors in Cultured Cerebellar Granule Cells”, Neurochemical Research, ), 605-612.
Aronica et al., “Status Epilepticus-Induced Alterations in Metabotropic Glutamate Receptor Expression in Young and Adult Rats”, J. Neurosci., ), .
Aronson et al., “Triiodothyronine Augmentation in the Treatment of Refractory Depression. A Meta-Analysis”, Arch Gen Psychiatry, 2-848.
Arriza et al., “Functional Comparisons of Three Glutamate Transporter Subtypes Cloned From Human Motor Cortex”, J. Neurosci., ), .
Arundine, “Molecular Mechanisms of Glutamate-Dependent Neurodegeneration in Ischemia and Traumatic Brain Injury”, Cellular and Molecular Life Sciences, 7-668.
Atlante, “Glutamate Neurotoxicity, Oxidative Stress and Mitochondria”, Febs Letters 497, .
Attwell et al., “Anticonvulsant and Glutamate Release-Inhibiting Properties of the Highly Potent Metabotropic Glutamate Receptor Agonist (2s,2′r, 3′r)-2-(2′,3′-Dicarboxycyclopropyl)Glycine (Dcg-Iv)”, Brain Res., -2), 138-143.
Auer et al., “Reduced Glutamate in the Anterior Cingulate Cortex in Depression: An in Vivo Proton Magnetic Resonance Spectroscopy Study”, Biol Psychiatry, ), 305-313.
Auerbach et al., “Mutations Causing Syndromic Autism Define an Axis of Synaptic Pathophysiology”, Nature, , 63-68.
Aultman et al., “Distinct Contributions of Glutamate and Dopamine Receptors to Temporal Aspects of Rodent Working Memory Using a Clinically Relevant Task”, Psychopharmacology (Berl), ), 353-364.
Austin et al., “Symptomatic and Neuroprotective Effects Following Activation of Nigral Group III Metabotropic Glutamate Receptors in Rodent Models of Parkinson's Disease”, British Journal of Pharmacology, , .
Australian Patent Application No. : Office Action dated Oct. 11, 2010, 2 pages.
Australian Patent Application No. : Office Action dated Mar. 19, 2010, 6 pages.
Australian Patent Application No. : Office Action dated May 29, 2012, 2 pages.
Australian Patent Application No. : Examiner's Report dated Nov. 3, 2010, 2 pages.
Australian Patent Application No. : Examiner's Report dated Oct. 31, 2012, 3 pages.
Awouters et al., “Astemizole: Effects on General Behavior and Interactions with the Central Nervous System”, Jap. Pharmacol. & Therapeutics, -89.
Ayalew et al., “Convergent Functional Genomics of Schizophrenia: From Comprehensive Understanding to Genetic Risk Prediction”, Molecular Psychiatry .
Ayan-Oshodi et al., “Adverse Events in Healthy Subjects Exposed to Single and Multiple Doses of Ly2140023 Monohydrate”, J Clin Psychopharmacol, 8-411.
Backstrom, “Suppression of Alcohol Self-Administration and Cue-Induced Reinstatement of Alcohol Seeking by the Mglu2/3 Receptor Agonist Ly379268 and the Mglu8 Receptor Agonist (S)-3,4-Dcpg”, Eur. J. Pharmacol., , 110-118.
Badawy et al., “Epilepsy: Ever-Changing States of Cortical Excitability” Neuroscience, -99.
Baffa et al., “Norepinephrine and Serotonin Transporter Genes: Impact on Treatment Response in Depression”, Neuropsychobiology, 1-131.
Bagby et al., “Psychosocial and Clinical Predictors of Response to Pharmacotherapy for Depression” J Psychiatry Neurosci, ), 250-7.
Bakker et al., “Activation of the Metabotropic Glutamate Receptor 2 (Mglu2) by Orthosteric and Allosteric Ligands”, Poster 642.6/E30 Presented at the 40th Annual Meeting of Society for Neuroscience 2010, 1 page.
Bakker et al., “Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment”, Neuron, ), 467-474.
Balastrieri et al., “Assessing Mixed Anxiety-Depressive Disorder. A National Primary Care Survey”, Psychiatry Research, , 197-201.
Balazs et al., “Metabotropic Glutamate Receptor Agonists Potentiate Cyclic Amp Formation Induced by Forskolin or Beta-Adrenergic Receptor Activation in Cerebral Cortical Astrocytes in Culture”, Journal of Neurochemistry, ), .
Bandelow et al., “Adjunct Quetiapine XR in Patients with Major Depressive Disorder: A Pooled Analysis of Data From Patients with Anxious Depression”, Abstracts of the 19th European Congress of Psychiatry, Mar. 2011, 1 page.
Barda et al., “Sar Study of a Subtype Selective Allosteric Potentiator of Metabotropic Glutamate 2 Receptor, N-(4-Phenoxyphenyl)-N-(3-Pyridinylmethyl)Ethanesulfonamide”, Bioorganic & Medicinal Chemistry Letters, 99-3102.
Barker et al., “A Temporally Distinct Role for Group I and Group II Metabotropic Glutamate Receptors in Object Recognition Memory”, Learn. Mem., ), 178-186.
Barnes et al., “A Review of Central 5-Ht Receptors and their Function”, Neuropharmacology, 83-1152.
Bar-Peled et al., “Distribution of Glutamate Transporter Subtypes During Human Brain Development”, J Neurochem., ), .
Barrett, “Mglur2-Positive Allosteric Modulators: Therapeutic Potential for Treating Cocaine Abuse?”, Neuropsychopharmacology, 07-2008.
Bartha et al., “Measurement of Glutamate and Glutamine in the Medial Prefrontal Cortex of Never-Treated Schizophrenic Patients and Healthy Controls by Proton Magnetic Resonance Spectroscopy”, Archives of General Psychiatry, ), 959-965.
Barton et al., “Comparison of the Effect of Glutamate Receptor Modulators in the 6 Hz and Maximal Electroshock Seizure Models”, Epilepsy Research, -26.
Basan et al., “Valproate for Schizophrenia”, Cochrane Collaboration, Cochrane Database Syst Rev.,
Batchelor et al., “Novel Synaptic Potentials in Cerebellar Purkinje Cells: Probable Mediation by Metabotropic Glutamate Receptors”, Neuropharmacology, ), 11-20.
Battaglia et al., “Selective Activation of Group-II Metabotropic Glutamate Receptors Is Protective Against Excitotoxic Neuronal Death,” European Journal of Pharmacology, -3), 271-274.
Bauer et al., “Extended Release Quetiapine as Adjunct to an Antidepressant in Patients with Major Depressive Disorder: Results of a Randomized, Placebo-Controlled, Double-Blind Study”, J Clin Psychiatry ), 540-549.
Bauzo et al., “Interactions Between the Mglur2/3 Agonist, Ly379268, and Cocaine on in Vivo Neurochemistry and Behavior in Squirrel Monkeys”, Pharmacol. Biochem. Behav., ), 204-210.
Bech et al., “Quantitative Rating of Depressive States”, Acta Psychiatr Scand, ), 161-170.
Bech, “Dose-Response Relationship of Pregabalin in Patients with Generalized Anxiety Disorder. A Pooled Analysis of Four Placebo-Controlled Trials”, Pharmacopsychiatry, 3-168.
Bech, “The Bech-Rafaelsen Melancholia Scale (Mes) in of Therapies in Depressive Disorders: A 20-Year Review of Its Use as Outcome Measure”, Acta Psychiatr Scand, ), 252-264.
Beesdo, “Incidence and Risk Patterns of Anxiety and Depressive Disorders and Categorization of Generalized Anxiety Disorder”, Arch Gen Psychiatry, ), 47-57.
Behrens et al., “Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons is Mediated by Nadph-Oxidase”, Science, , .
Belenikin et al., “Comparative Analysis of the Ligand-Binding Sites of the Metabotropic Glutamate Receptors Mglur1-Mglur8”, Doklady Biochemistry & Biophysics., , 251-256.
Bell et al., “Altered Synaptic Function in Alzheimer's Disease”, European Journal of Pharmacology, ), 11-21.
Bellani et al., “Brain Anatomy of Major Depression II. Focus on Amygdala”, Epidemiology and Psychiatric, Sciences, ), 33-36.
Bellesi et al., “The Mglur2/3 Agonist Ly379268 Blocks the Effects of Glt-I Upregulation on Prepulse Inhibition of the Startle Reflex in Adult Rats”, Neuropsychopharmacology, .
Bellesi et al., “The Mglur2/3 Agonist Ly379268 Blocks the Effects of Glt-1 Upregulation on Prepulse Inhibition of the Startle Reflex in Adult Rats”, Neuropsychopharmacology, ), .
Belousov et al., “Non-Cholinergic Excitation in Neurons After a Chronic Glutamate Receptor Blockade”, Neuroreport, ), 113-117.
Benarroch, “Metabotropic Glutamate Receptors: Synaptic Modulators and Therapeutic Targets for Neurologic Disease”, Neurology, ), 964-968.
Bence et al., “Sleep and Psychiatric Disorders. A Meta-Analysis”, Arch Gen Psychiatry, 1-670.
Beneyto et al., “Abnormal Glutamate Receptor Expression in the Medial Temporal Lobe in Schizophrenia and Mood Disorders”, Neuropsychopharmacology, ), .
Benilova et al., “The Toxic Aβ Oligomer and Alzheimer's Disease: An Emperor in Need of Clothes”, Nature Neuroscience, ), 349-357.
Benneyworth et al., “Chronic Phenethylamine Hallucinogen Treatment Alters Behavioral Sensitivity to a Metabotropic Glutamate 2/3 Receptor Agonist”, Neuropsychopharmacology, ), .
Benquet et al., “Two Distinct Signaling Pathways Upregulate Nmda Receptor Responses via Two Distinct Metabotropic Glutamate Receptor Subtypes”, Journal of Neuroscience, ), .
Benson et al., “A Comparison of Observational Studies and Randomized, Controlled Studies”, N Engl J Med., ), .
Bergink et al., “Metabotropic Glutamate II Receptor Agonists in Panic Disorder: A Double Blind Clinical Trial with Ly354740”, International Clinical Psychopharmacology, 1-293.
Berman et al., “The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study”, J Clin Psychiatry, 3-853.
Bermudo-Soriano, “New Perspectives in Glutamate and Anxiety”, Pharmacol Biochem Behav, 2011, Epub, No Page Numbers, Doi:10.1016/J.Pbb..
Berthele et al., “Distribution and Developmental Changes in Metabotropic Glutamate Receptor Messenger RNA Expression in the Rat Lumbar Spinal Cord”, Developmental Brain Research, ),}